Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study
In this medfyle
In the ASCEND study, asciminib demonstrated significant benefit as a first-line therapy for newly diagnosed CP-CML. With a median follow-up of 21 months, the study reported that 93% of patients achieved an early molecular response and 79% reached major molecular response by 12 months. The treatment exhibited excellent safety and tolerance, with a low discontinuation rate due to adverse events. These findings highlight asciminib as a leading candidate for frontline CP-CML therapy, offering hope for improved patient outcomes.
About this Medfyle
©2024-25 Medfyle. All rights reserved.
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in Blood, American Society of Hematology's official journal.
Original article: Yeung DT, Shanmuganathan N, Reynolds J, Branford S, Walia M, Yong ASM, Shortt J, Chee L, Viiala N, Cunningham I, Ross DM, D'Souza A, Wright M, Harrup R, Forsyth C, Filshie R, Lane S, Browett P, Grove C, Grigg AP, Hughes TP. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study. Blood. 2024 Nov 7;144(19):1993-2001.
